RxDoctor Payments Data

Emily Dempsey, NP

Nurse Practitioner · Beloit, WINPI 1437874930

Payments from drug & device makers

$606in general payments, 2019–2025

Across 10 payments — averaging $60.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$150
  • AstraZeneca$143
  • Medtronic$124
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$106
  • Novartis$25
  • Edwards Lifesciences$23
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$45675%
  • Education$15025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$606 in reported general payments places this provider in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$6,310
Medicare patients
69
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$45,682
EntrestoSacubitril/Valsartan13$17,821
Donepezil Hcl22$1,545
Quetiapine Fumarate69$803
Metoprolol Succinate58$684
ClopidogrelClopidogrel Bisulfate67$570
Nifedipine ErNifedipine16$568
Amiodarone Hcl20$509
Potassium Chloride18$502
Fludrocortisone Acetate16$478
Trazodone Hcl26$379
Carbidopa-LevodopaCarbidopa/Levodopa19$347
Escitalopram Oxalate41$336
Losartan Potassium35$332
Valsartan13$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$25$17,82113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Beloit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →